Dr. Uusinarkaus is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2610 Tenderfoot Hill St
Colorado Springs, CO 80906Phone+1 719-522-1133Fax+1 719-576-2025- Is this information wrong?
Summary
- Dr. Uusinarkaus is involved in medical education – he is an assistant professor of Family Medicine at the University of Colorado, Denver. He also has a passion for preventive cardiology, becoming certified in Clinical Lipidology the first year it was offered, in 2005. He has additional training as a specialist in the treatment of hypertension.
He is currently a board member of the South West Lipid Association – a regional entity of the National Lipid Association. In addition, he maintains an active research interest, participating as a Principal Investigator in many clinical trials involving new treatments for common ailments and diseases.
Education & Training
Christ Hospital/University of Cincinnati College of MedicineResidency, Family Medicine, 1994 - 1997
Loma Linda University School of MedicineClass of 1994
Certifications & Licensure
CO State Medical License 2001 - 2025
OH State Medical License 1995 - 2003- American Board of Family Medicine Family Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2011-2012
- Fellow (FAAFP) American Academy of Family Physicians, 2010
Clinical Trials
- Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM Start of enrollment: 2015 Sep 01
- Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL Start of enrollment: 2017 Apr 06
Publications & Presentations
PubMed
- 11 citationsImproved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials.Johan Jendle, Andreas L. Birkenfeld, William H. Polonsky, Robert Silver, Kari Uusinarkaus, Thomas Kruse Hansen, Jonas Håkan-Bloch, Sayeh Tadayon, Melanie J. Davies> ;Diabetes, Obesity & Metabolism. 2019 Oct 1
- 16 citationsThe Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase I...Kenneth E. Schmader, Myron J. Levin, Katrijn Grupping, Sean Matthews, David Butuk, Michael Chen, Mohamed El Idrissi, Laurence A Fissette, Charles Fogarty, Paul Hartley...> ;The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2019 Jul 12
Journal Articles
- The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine Upon the Physical Functioning and Quality of Life of Older Adults: An Open Phase III TrialMyron J Levin, David Butuk, Kenneth E Schmader, Charles Fogarty, Paul Hartley, Max Nevarez, Nicola P Klein, Kari Uusinarkaus, The Journals of Gerontology
Press Mentions
When Goals Are Not Met in Diabetes CareDecember 11th, 2017
Professional Memberships
- Fellow
Hospital Affiliations
UCHealth Memorial HospitalColorado Springs, Colorado
Penrose-St. Francis Health ServicesColorado Springs, Colorado
UCHealth Poudre Valley HospitalFort Collins, Colorado
University of Colorado HospitalAurora, Colorado
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
